Drug Trial Radar · NCT06395103
Substudy 01A: Zilovertamab Vedotin in Pediatric and Young Adult Participants With Hematologic Malignancies or Solid Tumors (MK-9999-01A/LIGHTBEAM-U01)
Last checked: Nov 19, 2026Latest source record: Oct 30, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
90
Planned (sponsor's estimate)
Start
Aug 16, 2024
Primary completion
Mar 31, 2029
Study completion Mar 31, 2029
Sponsor
- Lead sponsor
- Merck Sharp & Dohme LLCMerck & Co. (MRK)
- Sponsor type
- Industry
- First posted
- May 1, 2024
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 6 months, up to 25 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Substudy 01A is part of a platform study. The purpose of this study is to assess the efficacy and safety of zilovertamab vedotin in pediatric participants with relapsed or refractory B-cell acute lymphoblastic leukemia (B-ALL), diffuse large B-cell lymphoma (DLBCL)/Burkitt lymphoma, or neuroblastoma and in pediatric and young adult participants with Ewing sarcoma.
Conditions
- B-cell Acute Lymphoblastic Leukemia
- Diffuse Large B-cell Lymphoma
- Burkitt Lymphoma
- Neuroblastoma
- Ewing Sarcoma
Interventions
Zilovertamab vedotinBiological
Administered via IV infusion
Primary outcomes
What the sponsor says the trial is designed to measure.
- Part 1: Number of Participants from 1 to <18 years of Age Who Experience a Dose-Limiting Toxicity (DLT)Time frame: Up to 42 days
- Part 1: Number of Participants from 1 to <18 years of Age Who Experience One or More Adverse Events (AEs)Time frame: Up to approximately 54 months
- Part 1: Number of Participants from 1 to <18 years of Age Who Discontinue Study Treatment Due to AEsTime frame: Up to approximately 54 months
- Part 1: Number of Participants from 1 to <18 years of Age Who Receive Dose Modification Due to AEsTime frame: Up to approximately 54 months
- Part 1 and Part 2: Objective Response (OR) for Participants with B-Cell Acute Lymphoblastic Leukemia (B-ALL)Time frame: Up to approximately 54 months
- Part 1 and Part 2: OR for Participants with Diffuse Large B-Cell Lymphoma (DLBCL)/Burkitt Lymphoma, Neuroblastoma, and Ewing SarcomaTime frame: Up to approximately 54 months
Locations
71 sites in 23 countries. Site status is shown where the registry gives one.
Children's Hospital Los Angeles ( Site 1006)
Los Angeles, California · Recruiting
Children's Hospital Colorado-Center for Cancer and Blood Disorders ( Site 1016)
Aurora, Colorado · Recruiting
Yale New Haven Hospital ( Site 1012)
New Haven, Connecticut · Recruiting
Johns Hopkins All Children's Hospital ( Site 1025)
St. Petersburg, Florida · Recruiting
University of Iowa Health Care. ( Site 1017)
Iowa City, Iowa · Recruiting
Dana-Farber Cancer Institute ( Site 1013)
Boston, Massachusetts · Recruiting
Corewell Health ( Site 1001)
Grand Rapids, Michigan · Recruiting
Children's Mercy Hospital ( Site 1024)
Kansas City, Missouri · Recruiting
Rutgers Cancer Institute of New Jersey ( Site 1008)
New Brunswick, New Jersey · Recruiting
Memorial Sloan Kettering Cancer Center ( Site 1010)
New York, New York · Recruiting
New York Medical College ( Site 1023)
Valhalla, New York · Recruiting
Sanford Fargo Medical Center-Roger Maris Cancer Center ( Site 1003)
Fargo, North Dakota · Recruiting
Oregon Health and Science University ( Site 1004)
Portland, Oregon · Recruiting
Children's Hospital of Philadelphia (CHOP) ( Site 1021)
Philadelphia, Pennsylvania · Recruiting
Sanford Children's Hospital-Sanford Children's Specialty Clinic ( Site 1015)
Sioux Falls, South Dakota · Recruiting
University of Texas MD Anderson Cancer Center ( Site 1007)
Houston, Texas · Recruiting
Intermountain - Primary Children's Hospital ( Site 1014)
Salt Lake City, Utah · Recruiting
Sydney Children's Hospital ( Site 1997)
Randwick, New South Wales, Australia · Recruiting
Queensland Children's Hospital-Oncology & Haematology ( Site 1996)
Brisbane, Queensland, Australia · Recruiting
Royal Children's Hospital-Children's Cancer Centre ( Site 1994)
Melbourne, Victoria, Australia · Recruiting
UZ Gent ( Site 1428)
Ghent, Oost-Vlaanderen, Belgium · Recruiting
Hospital Erasto Gaertner-CEPEP - Pesquisa Clínica ( Site 1268)
Curitiba, Paraná, Brazil · Completed
Hospital de Clinicas de Porto Alegre ( Site 1265)
Porto Alegre, Rio Grande do Sul, Brazil · Recruiting
Fundação Pio XII - Hospital de Câncer de Barretos ( Site 1264)
Barretos, São Paulo, Brazil · Recruiting
Fundação Faculdade Regional de Medicina de São José do Rio Preto-Centro Integrado de Pesquisa ( Site 1267)
São José do Rio Preto, São Paulo, Brazil · Recruiting
Alberta Children's Hospital ( Site 1227)
Calgary, Alberta, Canada · Recruiting
The Hospital for Sick Children ( Site 1225)
Toronto, Ontario, Canada · Recruiting
McGill University Health Centre-Pediatric HematologyOncology ( Site 1223)
Montreal, Quebec, Canada · Recruiting
Hospital Clínico Regional Dr. Guillermo Grant Benavente ( Site 1881)
Concepción, Biobio, Chile · Recruiting
Hospital Luis Calvo Mackenna ( Site 1879)
Santiago, Region M. de Santiago, Chile · Recruiting
Hospital Carlos Van Buren ( Site 1880)
Valparaíso, Valparaiso, Chile · Recruiting
Hospital Pablo Tobon Uribe ( Site 1923)
Medellín, Antioquia, Colombia · Recruiting
Clinica de la Costa S.A.S.-Clinical Research Oncology & Hematology -Pediatric ( Site 1924)
Barranquilla, Atlántico, Colombia · Recruiting
IMAT S.A.S ( Site 1921)
Montería, Departamento de Córdoba, Colombia · Recruiting
Detska nemocnice FN Brno ( Site 1388)
Brno, Brno-mesto, Czechia · Recruiting
Fakultni nemocnice v Motole-Klinika detske hematologie a onkologie ( Site 1387)
Prague, Praha 5, Czechia · Recruiting
Rigshospitalet-Department of paediatrics and adolescent medicine, Section of Paed haem-onc ( Site 1467)
Copenhagen, Capital Region, Denmark · Recruiting
CHU de Bordeaux. Hopital Pellegrin ( Site 1105)
Bordeaux, Aquitaine, France · Recruiting
CENTRE LEON BERARD-IHOPE (pediatrric oncology) ( Site 1100)
Lyon, Auvergne-Rhône-Alpes, France · Recruiting
Gustave Roussy ( Site 1103)
Villejuif, Île-de-France Region, France · Recruiting
Showing 40 of 71 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.